Major Outcomes in Elderly Patients With Self-Management of Oral Anticoagulation (SPOG60+)
Launched by MEDICAL UNIVERSITY OF GRAZ · Nov 17, 2007
Trial Information
Current as of June 14, 2025
Completed
Keywords
ClinConnect Summary
Oral anticoagulation (OAC) has been shown to be highly effective in preventing thromboembolic complications in patients for whom it is indicated. Numerous studies have documented that elderly patients seem to benefit most from OAC therapy. Atrial fibrillation (AF), the incidence of which increases with age and approaches 10% for individuals aged ≥ 80 years, carries the main risk for stroke, and among elderly patients without antithrombotic therapy,
Despite its proven benefit, numerous studies have reported reluctance in prescribing OAC due to a variety of barriers, especially in the elderl...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • long-term anticoagulation
- • either with phenprocoumon or acenocoumarol
- • age ≥ 60 years
- • written informed consent
- Exclusion Criteria:
- • previous participation in a self-management OAC programme
- • severe cognitive
- • terminal illness
About Medical University Of Graz
The Medical University of Graz, a leading institution in Austria, is dedicated to advancing medical knowledge and improving patient care through innovative research and clinical trials. Renowned for its interdisciplinary approach, the university collaborates with various healthcare professionals and researchers to explore cutting-edge therapies and treatments. With a commitment to ethical standards and patient safety, the Medical University of Graz actively contributes to the global medical community by facilitating rigorous clinical trials that aim to translate scientific discoveries into practical applications for improved health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vienna, , Austria
Graz, Styria, Austria
Cologne, , Germany
Patients applied
Trial Officials
Ulrike Didjurgeit, psychologist
Principal Investigator
DIeM - Institute for Evidence-based Medicine, Cologne, Germany
Andrea Siebenhofer, consultant
Study Chair
Department of Internal Medicine, Medical University of Graz, Austria
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials